The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer’s Disease Treatment

Our research over the past decade has compellingly demonstrated the potential of Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor agonists in Alzheimer’s disease (AD) treatment. These agonists facilitate the conversation of pro-inflammatory monocytes into patrolling mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghareghani, Majid, Rivest, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341981/
https://www.ncbi.nlm.nih.gov/pubmed/37446081
http://dx.doi.org/10.3390/ijms241310905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341981/
https://www.ncbi.nlm.nih.gov/pubmed/37446081
http://dx.doi.org/10.3390/ijms241310905

Ejemplares similares